1198PD - German Clinical Registries: Neoadjuvant chemoradiotherapy in non small cell lung cancer

Date 29 September 2014
Event ESMO 2014
Session NSCLC, metastatic
Topics Anticancer agents
Surgical oncology
Non-small-cell lung cancer
Biological therapy
Radiation oncology
Presenter Maike De Wit
Citation Annals of Oncology (2014) 25 (suppl_4): iv417-iv425. 10.1093/annonc/mdu348
Authors M. De Wit1, W. Pankow2, S. Eggeling3, B. Schicke4, A. Reinecke4
  • 1Hematology And Oncology, Vivantes Klinikum Neukölln, 12351 - Berlin/DE
  • 2Pneumology And Infectiology, Vivantes Klinikum Neukölln, 12351 - Berlin/DE
  • 3Thoracic Surgery, Vivantes Klinikum Neukölln, 12351 - Berlin/DE
  • 4Xx, Tumorzentrum Berlin, Berlin/DE




In 2000 and 2011 the “Arbeitsgemeinschaft Deutscher Tumorzentren (ADT)” and the “Kooperationsverband Qualitätssicherung durch klinische Krebsregister (KoQK)” collected the German data of clinical cancer registries for certain tumour entities using a standardized data sheet. These data were analyzed in February 2014, and we report the results for neoadjuvant therapy in non small lung cancer (NSCLC).


A total of 129740 patients with NSCLC were submitted for analysis. Of 10819 (41.4%) in stage IIIA 9356 presented with stage IIIA (N2) (35.8%), while 15325 (58.6%) already had reached stage IIIB. Most often squamous cell carcinoma (52.3%) was diagnosed followed by adenocarcinoma (32.5%) and large cell carcinoma (5.2%), but a large percentage of “other non small cell lung cancer” (10%) were included.


“Neoadjuvant therapy” was documented in 1441 patients but 393 of these underwent chemoradiotherapy alone and did not proceed to surgery and thus were omitted in the further evaluation. In the remaining 1048 radiotherapy (n = 53), chemotherapy (n = 328) or chemoradiotherapy (n = 604) preceded surgery. Comparing patients who received neoaduvant therapy with patients who did not receive neoadjuvant treatment stages and gender showed no significant differences but patients receiving neoadjuvant treatment in the mean were younger (women 60 vs. 66 years, men 62 vs. 67 years). Patients who had been treated neoadjuvant lived longer (median 25 vs. 12 months) and showed better therapeutic response, but at the same time local relapses or metastases were registered more frequently.


We conclude that patients who received neoadjuvant therapy lived longer. Whether this is due to their younger age (and probably better ECOG at diagnosis) can not be found out in this retrospective analysis of non-randomized patients.


All authors have declared no conflicts of interest.